ACRP CP FINAL EXAMS AND CERTIFICATIONS BUNDLE (COMPLETE
COURSE)NEWEST ACTUAL EXAM COMPLETE QUESTIONS AND
CORRECT DETAILED ANSWERS (VERIFIED ANSWERS) |ALREADY
GRADED A+(2025)
Crossover - (answer)when each subject is randomized to a sequence of two or more treatments and
hence acts as their own control for treatment comparisons
Parallel - (answer)when subjects are randomized to 1 of 2 or more arms, each arm being allocated a
different treatment. Each treatment will include their investigational product at one or more doses, and
one or more control treatments, such as placebo and/or an active comparator
A sponsor is developing an IP for treatment of a medical condition where there is one additional
marketed product approved for treatment of the condition. The sponsor believes their product works as
well or better than the current treatment with fewer side effects. What is the most-likely study design
they will use to test the efficacy of the IP? - (answer)Non-Inferiority
What type of clinical trial most likely requires enrollment of the largest number of research subjects? -
(answer)Therapeutic confirmatory (aka Pivotal Trial, Ph III, or Comparative Efficacy)
Minimum number of membors on an IRB/IEC - (answer)5 .. lay people and medical professionals can be
part of the IRB/IEC
Who is responsible for providing the protocol - (answer)The Sponsor
The purpose of the SIV is to - (answer)-review standard procedures
-review the protocol
-review the blank eCRFs
Minimum SAE reporting requirements - (answer)- Subject details (ID not name)
- IP
, ACRP CP FINAL EXAMS AND CERTIFICATIONS BUNDLE (COMPLETE
COURSE)NEWEST ACTUAL EXAM COMPLETE QUESTIONS AND
CORRECT DETAILED ANSWERS (VERIFIED ANSWERS) |ALREADY
GRADED A+(2025)
- Interventions for the event that is being reported
- Details of the event
- Details on the reporter of the event
- Admin and sponsor or company details/
Vulnerable subjects - (answer)- Junior members of the medical profession
- Employees of a pharmaceutical company
- Military personnel
- Pregnant Women
- Prisoners
IRB/IEC Evaluates - (answer)- The rights, safety, and well-being of the subjects participating in the trial
- The subject selection procedure
- The scientific tenability of the trial
Serious Adverse Event (SAE) - (answer)- results in death, is life threatening, requires inpatient admission,
prolonged admission, congenital anomaly, or persistent incapacity
-death itself is not neccessarily an sae
- Seriousness does not equal severity in that Serious requires reporting while severe may not.. Severe
may just be used to describe an AE
- Must be reported by sponsor to authorities within 15 calendars days from sponsors first knowledge of
the event
Adverse Drug Reaction (ADR) - (answer)- All noxious and unintended response that is related to any dose
COURSE)NEWEST ACTUAL EXAM COMPLETE QUESTIONS AND
CORRECT DETAILED ANSWERS (VERIFIED ANSWERS) |ALREADY
GRADED A+(2025)
Crossover - (answer)when each subject is randomized to a sequence of two or more treatments and
hence acts as their own control for treatment comparisons
Parallel - (answer)when subjects are randomized to 1 of 2 or more arms, each arm being allocated a
different treatment. Each treatment will include their investigational product at one or more doses, and
one or more control treatments, such as placebo and/or an active comparator
A sponsor is developing an IP for treatment of a medical condition where there is one additional
marketed product approved for treatment of the condition. The sponsor believes their product works as
well or better than the current treatment with fewer side effects. What is the most-likely study design
they will use to test the efficacy of the IP? - (answer)Non-Inferiority
What type of clinical trial most likely requires enrollment of the largest number of research subjects? -
(answer)Therapeutic confirmatory (aka Pivotal Trial, Ph III, or Comparative Efficacy)
Minimum number of membors on an IRB/IEC - (answer)5 .. lay people and medical professionals can be
part of the IRB/IEC
Who is responsible for providing the protocol - (answer)The Sponsor
The purpose of the SIV is to - (answer)-review standard procedures
-review the protocol
-review the blank eCRFs
Minimum SAE reporting requirements - (answer)- Subject details (ID not name)
- IP
, ACRP CP FINAL EXAMS AND CERTIFICATIONS BUNDLE (COMPLETE
COURSE)NEWEST ACTUAL EXAM COMPLETE QUESTIONS AND
CORRECT DETAILED ANSWERS (VERIFIED ANSWERS) |ALREADY
GRADED A+(2025)
- Interventions for the event that is being reported
- Details of the event
- Details on the reporter of the event
- Admin and sponsor or company details/
Vulnerable subjects - (answer)- Junior members of the medical profession
- Employees of a pharmaceutical company
- Military personnel
- Pregnant Women
- Prisoners
IRB/IEC Evaluates - (answer)- The rights, safety, and well-being of the subjects participating in the trial
- The subject selection procedure
- The scientific tenability of the trial
Serious Adverse Event (SAE) - (answer)- results in death, is life threatening, requires inpatient admission,
prolonged admission, congenital anomaly, or persistent incapacity
-death itself is not neccessarily an sae
- Seriousness does not equal severity in that Serious requires reporting while severe may not.. Severe
may just be used to describe an AE
- Must be reported by sponsor to authorities within 15 calendars days from sponsors first knowledge of
the event
Adverse Drug Reaction (ADR) - (answer)- All noxious and unintended response that is related to any dose
